Comparison of Recovery Profile After TIVA Between Remimazolam With Flumazenil and Propofol

• Status: Not yet recruiting
• Trial end date: 2022-08-10
• Target enrollment: 0
• Participant gender: All

Summary

This prospective, randomized, single-blinded study is designed to compare the recovery profile between propofol-based total intravenous anesthesia (TIVA) and remimazolam-based TIVA in patients undergoing thyroidectomy. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery. We hypothesize that remimazolam-based TIVA antagonized by flumazenil can significantly shorten the time from the end of anesthetic administration to eye-opening compared to propofol-based TIVA.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: Hana Pharm. Co., Ltd
• Treatments: Propofol

Criteria

Inclusion Criteria:

• Patients scheduled to undergo elective thyroidectomy under general anesthesia

• American Society of Anesthesiologists (ASA)physical classification I-II

• Willingness and ability to sign an informed consent document

Exclusion Criteria:

• American Society of Anesthesiologists (ASA)physical classification III or more

• BMI > 40kg/m^2

• Allergies to anesthetic or analgesic medications (benzodiazepines, propofol, remifentanil, fentanyl citrate, rocuronium bromide, sugammadex, flumazenil)

• Patients who receive mechanical ventilation morethan 2 hours after surgery

• Patients who receive the following medications within 24 hours prior to general anesthetics: anxiolytics, antipsychotics, rifampicin, succinycholine, neostigmine, flumazenil, cyclosporin

• Patients with galactose intolerance or Lapp Lactase deficiency or glucose-galactose malabsorption

• Medical or psychological disease that can affect the treatment response